Dr Dawn Nixon, PSYD in Bayfield, WI - Psychologist

Dr Dawn Nixon, PSYD is a Psychologist based in Bayfield, Wisconsin. Dr Dawn Nixon is licensed to practice in Wisconsin (license number 2809-057) and her current practice location is 88385 Pike Rd, Bayfield, Wisconsin. She can be reached at her office (for appointments etc.) via phone at (715) 779-5030.

NPI number for Dr Dawn Nixon is 1396073821 and her current mailing address is 86360 Valley Rd, Bayfield, Wisconsin. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1396073821.

Contact Information

	Dr Dawn Nixon, PSYD
	88385 Pike Rd, Bayfield, WI 54814-4818
	(715) 779-5030
	(715) 779-5046

Healthcare Provider's Profile

Full Name	Dr Dawn Nixon
Gender	Female
Speciality	Psychologist
Location	88385 Pike Rd, Bayfield, Wisconsin
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1396073821
Provider Enumeration Date: 11/20/2009
Last Update Date: 01/07/2015

Medical Identifiers

Medical identifiers for Dr Dawn Nixon such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1396073821	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103T00000X	Psychologist	2809-057 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Dawn Nixon is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Dawn Nixon, PSYD 86360 Valley Rd, Bayfield, WI 54814-4557 Ph: (715) 779-5030	Dr Dawn Nixon, PSYD 88385 Pike Rd, Bayfield, WI 54814-4818 Ph: (715) 779-5030

News Archive

Pharmexa vaccine is designed to induce antibody responses against the HER-2 protein

Pharmexa presents data from the HER-2 Protein AutoVac™ breast cancer trial at a Conference in Hamburg Summary: Pharmexa is presenting data from the first clinical trial in USA with the HER-2 Protein AutoVac™ vaccine at the 4th European Breast Cancer Conference (EBCC) in Hamburg, Germany.

Carnegie professor receives NIH Director's New Innovator Award

Kathryn Whitehead, assistant professor of chemical engineering at Carnegie Mellon University, has been awarded a 2018 National Institutes of Health (NIH) Director's New Innovator Award for her project titled "Fate, Function, and Genetic Engineering of Breast Milk Cells for Infant Therapy."

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

Study demonstrates pharmacists ability to identify & refer patients at-risk for fractures

Results from Project ImPACT: Osteoporosis were discussed today during the Annual Meeting of the American Pharmacists Association. Published in the March/April 2004 issue of the Journal of the American Pharmacists Association the authors, Jean-Venable "Kelly" Goode, Kim Swiger, and Benjamin M. Bluml, suggest that when patients, pharmacists and physicians collaborate closely, using pharmacy-based testing to identify and refer patients who are at-risk for future fracture that breakthrough results are possible.

Dr Dawn Nixon, PSYD - Psychologist in Bayfield, WI